论文部分内容阅读
我国是病毒性乙型肝炎(以下简称乙肝)高发区之一,当前尚无治疗乙肝的特效方法,应用乙肝疼苗保护易感人群是控制乙肝流行最有效的措施。乙肝疫苗的免疫原性及安全性观察,国外已有不少报导,中国生产的同类疫苗也有报导我们于1985年3月起对卫生部北京生物制品研究所845-3批乙肝疫苗免疫应答及其安全性做人体观察,现将结果报告如下: 材料和方法一、疫苗:卫生部北京生物制品研究所生
China is one of the high incidence areas of viral hepatitis B (hereinafter referred to as hepatitis B). Currently, there is no specific treatment for hepatitis B. The application of hepatitis B pain vaccine to protect susceptible people is the most effective measure to control the epidemic of hepatitis B. Hepatitis B vaccine immunogenicity and safety observed that there have been many reports abroad, similar vaccines produced in China have also reported that we in March 1985 on the Ministry of Health Beijing Institute of Biological Products 845-3 batch of hepatitis B vaccine immune response and its Safety of human observation, the results are reported as follows: Materials and methods First, the vaccine: Ministry of Health Beijing Institute of Biological Products